EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex—An update

Riccardo Balestri iD, Laura Rizzoli, Annalisa Pedrolli, Silvana Anna Maria Urru, Giulia Rech, Iria Neri, Carlo R Girardelli, Michela Magnano iD

Journal of the European Academy of Dermatology and Venereology · 2023-03 · 37 (3) · 474-487

DOI: 10.1111/jdv.18693 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 05.11.2022. Verfasst von Riccardo Balestri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Outpatient Consultation for Rare Diseases, Trento, Italy. Hauptthemen laut MEDLINE: Tuberous Sclerosis, Angiofibroma, Facial Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous syndrome causing hamartomatous growths in multiple organs. Facial angiofibromas occur in up to 80% of patients and can be highly disfiguring. Treatment for these lesions is challenging. Recently, topical rapamycin has been proposed as an effective option to treat angiofibromas but a commercially available compound has not yet been developed in Europe. We conducted a retrospective review with the aim to update the current data on the use of topical rapamycin in the treatment of angiofibromas in TSC, focusing on the optimal concentration and trying to establish which vehicle should be preferred. Thirty‐nine reports describing the use of topical rapamycin in the treatment of angiofibromas in TSC were considered, involving a total of 483 patients. An improvement of the lesions has been shown in over 90% of subjects, particularly if the treatment was started at early stages. Several different formulations (ointment, gel, solution and cream) with a wide range of concentrations (0.003%–1%) were proposed, of which a pharmacological analysis has also been performed. Topical rapamycin can be considered an effective and safe option for the treatment and the prevention of facial angiofibromas in younger patients, but the best formulation has yet to be established. Our review demonstrates that ointment and gel should be preferred, but it is not clear which concentration is optimal. However, according to this study, the 0.1% concentration represents the first choice. Long‐term and comparative studies between topical rapamycin formulations are required in order to establish which treatment has a better outcome and lower recurrence rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberous SclerosisAngiofibromaFacial NeoplasmsHumansSirolimusMTOR InhibitorsOintmentsImmunosuppressive AgentsTOR Serine-Threonine Kinases

Substanzen

SirolimusMTOR InhibitorsOintmentsImmunosuppressive AgentsMTOR protein, humanTOR Serine-Threonine Kinases

Autor:innen und Institutionen

  • Division of Dermatology, Outpatient Consultation for Rare Diseases, Trento, Italy.
  • Division of Pediatrics, Outpatient Consultation for Rare Diseases, Trento, Italy.
  • Hospital Pharmacy Unit, Trento General Hospital, Autonomous Province of Trento, Trento, Italy.
  • Dermatology Unit, IRCSS Policlinico di S. Orsola, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

ORCID-Profile: Riccardo Balestri, Michela Magnano

Zitieren

APA

Balestri, R., Rizzoli, L., Pedrolli, A., Urru, S. A. M., Rech, G., Neri, I., Girardelli, C. R., & Magnano, M. (2023). Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex—An update. Journal of the European Academy of Dermatology and Venereology, 37(3), 474-487. https://doi.org/10.1111/jdv.18693

Vancouver

Balestri R, Rizzoli L, Pedrolli A, Urru SAM, Rech G, Neri I, et al. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex—An update. Journal of the European Academy of Dermatology and Venereology. 2023;37(3):474-487. doi:10.1111/jdv.18693

BibTeX
@article{Balestri2023,
  author = {Balestri, Riccardo and Rizzoli, Laura and Pedrolli, Annalisa and Urru, Silvana Anna Maria and Rech, Giulia and Neri, Iria and Girardelli, Carlo R and Magnano, Michela},
  title = {Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex—An update},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  volume = {37},
  number = {3},
  pages = {474--487},
  doi = {10.1111/jdv.18693}
}
Kostenlos starten →